LanteRNA provides nucleic acid label development and drug delivery process services.
LanteRNA has raised $517K in total funding. The most recent round was Seed. The last funding was announced in May 2024.
LanteRNA's investors include Chalmers Ventures AB.
LanteRNA is headquartered in Gothenburg, Sweden.
LanteRNA provides nucleic acid label development and drug delivery process services.
LanteRNA is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LanteRNA — Funding & Investors." VCBacked, May 6, 2024, https://www.vcbacked.co/company/lanterna. Accessed September 30, 2026.
VCBacked. (2024). LanteRNA — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/lanterna
{{cite web |title=LanteRNA — Funding & Investors |url=https://www.vcbacked.co/company/lanterna |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated